Physician profile
Ruidi Wang
NPI 1710321310
$1,989.91
in general payments reported to CMS, 2019-2025
19 companies · $422 in 2025
The $422 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $68.71 · 2021: $233 · 2022: $260 · 2023: $397 · 2024: $489 · 2025: $422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,290 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,289.62 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $423.85 | 2023-2025 | Vyzulta, Miebo, Xiidra |
| Alcon Vision LLC | $356.92 | 2019-2024 | Rocklatan, Clareon |
| Novartis Pharmaceuticals Corporation | $233.18 | 2019-2023 | |
| Horizon Therapeutics Plc | $130.26 | 2021-2023 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $120.06 | 2023-2025 | Tecnis Iol |
| Tarsus Pharmaceuticals, INC. | $112.46 | 2024-2025 | Xdemvy |
| Harrow Eye, LLC | $100.72 | 2024-2025 | Vevye |
| Mallinckrodt Hospital Products INC. | $92.99 | 2021 | |
| Amgen INC. | $86.57 | 2024 | Tepezza |
| Abbvie INC. | $58.46 | 2022-2024 | Durysta |
| Dompe US, INC. | $56.94 | 2020-2024 | Oxervate |
| Sun Pharmaceutical Industries INC. | $42.38 | 2023-2024 | Cequa |
| Allergan, INC. | $40.36 | 2021 | |
| Astellas Pharma US INC | $33.27 | 2024 | Izervay |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $29.94 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $29.20 | 2025 | Vabysmo |
| Glaukos Corporation | $17.32 | 2024 | Idose |
| Shire North American Group INC | $13.23 | 2019 | |
| Sight Sciences, INC. | $11.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruidi Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.